MarketCap
Facebook
X
Telegram
Navidea Biopharmaceuticals Accounts Receivables | NAVB
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Navidea Biopharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 630 | 93 K | 2.99 M | 901 K | 21.2 K | 8.14 M | 203 K | 10.4 K | 817 K | 1.15 M | 17.6 K | 15.8 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.14 M | 630 | 1.2 M |
Quarterly Accounts Receivables Navidea Biopharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 93 K | - | - | - | 2.99 M | - | - | 1.7 M | 901 K | 146 K | 207 K | 9.87 K | 21.2 K | 86.9 K | 374 K | 13 M | 8.14 M | 8.04 M | 8.38 M | 7.19 M | 203 K | 3.47 M | 3.5 M | 2.8 M | 10.4 K | 1.91 M | 1.83 M | 1.21 M | 817 K | 1.47 M | 487 K | 587 K | 1.15 M | 158 K | 86.4 K | 17.5 K | 17.6 K | 22.8 K | 17.6 K | 17.6 K | 15.8 K | 15.8 K | 2.03 M | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13 M | 9.87 K | 1.92 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
25.6 M | $ 51.7 | 1.83 % | $ 1.5 B |  USA |
 |
Bicycle Therapeutics plc
BCYC
|
2.04 M | $ 3.73 | 3.61 % | $ 258 M |  Britain |
 |
Clovis Oncology
CLVS
|
26.9 M | - | -7.23 % | $ 13 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
218 K | - | - | $ 401 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
908 M | $ 61.35 | 0.06 % | $ 11.8 B | USA |
 |
Benitec Biopharma
BNTC
|
4 K | $ 9.64 | 0.46 % | $ 449 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
97 K | - | - | $ 384 M | Britain |
 |
G1 Therapeutics
GTHX
|
12.7 M | - | - | $ 370 M | USA |
 |
Catalyst Biosciences
CBIO
|
31.1 M | $ 14.24 | 0.35 % | $ 1.27 B | USA |
 |
C4 Therapeutics
CCCC
|
2.4 M | $ 3.03 | 0.3 % | $ 251 M | USA |
 |
Codexis
CDXS
|
10 M | $ 1.37 | 1.45 % | $ 119 M | USA |
 |
Cerus Corporation
CERS
|
30.4 M | $ 2.61 | 0.38 % | $ 497 M | USA |
 |
AbbVie
ABBV
|
12.6 B | $ 265.12 | 0.09 % | $ 469 B | USA |
 |
Humanigen
HGEN
|
44 K | - | -81.12 % | $ 4.28 M | USA |
 |
Coherus BioSciences
CHRS
|
17.8 M | $ 1.17 | 1.48 % | $ 137 M | USA |
 |
AbCellera Biologics
ABCL
|
39.4 M | $ 12.65 | 2.76 % | $ 3.78 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
3 | $ 5.43 | 2.65 % | $ 288 M | USA |
 |
Celldex Therapeutics
CLDX
|
2.02 M | $ 31.48 | 1.16 % | $ 2.09 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
1 K | $ 4.12 | 1.98 % | $ 50.3 M |  Israel |
 |
IGM Biosciences
IGMS
|
800 K | - | - | $ 76.9 M | USA |
 |
Karuna Therapeutics
KRTX
|
57 K | - | - | $ 12.2 B | USA |
 |
Cocrystal Pharma
COCP
|
556 K | $ 1.15 | 1.67 % | $ 13 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
592 K | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Collegium Pharmaceutical
COLL
|
211 M | $ 22.64 | 0.85 % | $ 717 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
59.8 M | $ 118.51 | 4.93 % | $ 12.3 B | USA |
 |
Chimerix
CMRX
|
57 K | - | - | $ 756 M | USA |
 |
Curis
CRIS
|
3.35 M | $ 0.88 | 0.85 % | $ 11.6 M | USA |
 |
CorMedix
CRMD
|
171 M | $ 7.77 | 1.04 % | $ 560 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
25 M | $ 55.7 | 0.23 % | $ 5.01 B |  Schweiz |
 |
Corvus Pharmaceuticals
CRVS
|
37 K | $ 11.8 | 8.21 % | $ 932 M | USA |
 |
Champions Oncology
CSBR
|
13.2 M | $ 4.95 | 0.38 % | $ 68.5 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
1.45 M | $ 4.88 | 0.62 % | $ 935 M | Canada |
 |
Cue Biopharma
CUE
|
5.55 M | $ 32.85 | 3.6 % | $ 3.11 B | USA |
 |
CEL-SCI Corporation
CVM
|
54.9 K | $ 1.72 | 2.38 % | $ 13.8 M | USA |